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Abstract
Background: PHF21A has been associated with intellectual disability and craniofacial anomalies based on its
deletion in the Potocki-Shaffer syndrome region at 11p11.2 and its disruption in three patients with balanced
translocations. In addition, three patients with de novo truncating mutations in PHF21A were reported recently.
Here, we analyze genomic data from seven unrelated individuals with mutations in PHF21A and provide detailed
clinical descriptions, further expanding the phenotype associated with PHF21A haploinsufficiency.
Methods: Diagnostic trio whole exome sequencing, Sanger sequencing, use of GeneMatcher, targeted gene panel
sequencing, and MiSeq sequencing techniques were used to identify and confirm variants. RT-qPCR was used to
measure the normal expression pattern of PHF21A in multiple human tissues including 13 different brain tissues.
Protein-DNA modeling was performed to substantiate the pathogenicity of the missense mutation.
Results: We have identified seven heterozygous coding mutations, among which six are de novo (not maternal in one).
Mutations include four frameshifts, one nonsense mutation in two patients, and one heterozygous missense mutation in
the AT Hook domain, predicted to be deleterious and likely to cause loss of PHF21A function. We also found a new C-
terminal domain composed of an intrinsically disordered region. This domain is truncated in six patients and thus likely to
play an important role in the function of PHF21A, suggesting that haploinsufficiency is the likely underlying mechanism in
the phenotype of seven patients. Our results extend the phenotypic spectrum of PHF21A mutations by adding autism
spectrum disorder, epilepsy, hypotonia, and neurobehavioral problems. Furthermore, PHF21A is highly expressed in the
human fetal brain, which is consistent with the neurodevelopmental phenotype.
Conclusion: Deleterious nonsense, frameshift, and missense mutations disrupting the AT Hook domain and/or an
intrinsically disordered region in PHF21A were found to be associated with autism spectrum disorder, epilepsy, hypotonia,
neurobehavioral problems, tapering fingers, clinodactyly, and syndactyly, in addition to intellectual disability and
craniofacial anomalies. This suggests that PHF21A is involved in autism spectrum disorder and intellectual disability, and its
haploinsufficiency causes a diverse neurological phenotype.
Keywords: PHF21A, BHC80, Intellectual disability (ID), Autism spectrum disorder (ASD), Neurodevelopmental disorders,
Potocki-Shaffer syndrome (PSS), AT Hook domain, Intrinsically disordered region (IDR), KDM1A
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Background
The Potocki-Shaffer syndrome (PSS [MIM 601224]) is
characterized by intellectual disability (ID), craniofacial
anomalies, multiple exostoses, and biparietal foramina. It
is a contiguous gene deletion disorder caused by hap-
loinsufficiency of multiple, functionally unrelated yet
physically contiguous genes on chromosome 11p11.2.
Two genes within the ~ 2.1Mb PSS genomic interval
have been shown to contribute to two major PSS pheno-
types: EXT2 (MIM 608210) [1] for multiple exostoses
and ALX4 (MIM 605420) [2, 3] for biparietal foramina.
We reported the association of a third gene, PHF21A
(MIM 608325), with ID and craniofacial anomalies, by
observing its truncation in three unrelated individuals
with balanced translocations and by comparative dele-
tion mapping in other individuals with PSS [4].
We have previously shown that the balanced chromo-
somal translocations truncating PHF21A in two unre-
lated patients resulted in the relaxation of repression of
the KDM1A target neuronal gene, SCN3A, by reducing
KDM1A occupancy at the SCN3A promoter. This obser-
vation led us to conclude that the disruption of PHF21A
resulted in transcriptional misregulation. We then
showed that the suppression of phf21a in zebrafish re-
sulted in neuronal apoptosis and craniofacial anomalies,
providing additional evidence that PHF21A deficiency
was responsible for the ID and craniofacial anomalies
observed in our patients with balanced translocations
[4]. This implication of PHF21A in ID and craniofacial
anomalies was further supported by the discovery of two
more multigenic microdeletions encompassing this gene
in two independent patients with a similar phenotype [5,
6] and one microdeletion at 11p11.2 that does not in-
clude PHF21A in a patient without ID [7].
During the preparation of this manuscript, three indi-
viduals carrying de novo truncated variants within
PHF21A have been published. Among three patients
with ID and craniofacial anomalies, epilepsy was present
in case 1, autism spectrum disorder (ASD) in case 2, and
overgrowth with macrocephaly in cases 1 and 3. The au-
thors have concluded that PHF21A haploinsufficiency
results in ID and craniofacial anomalies, and possibly
contributes to ASD, epilepsy, and overgrowth [8]. Here,
we report seven individuals with heterozygous patho-
genic sequence variants within the coding region of
PHF21A and provide detailed clinical descriptions, fur-
ther expanding the phenotype associated with PHF21A
haploinsufficiency.
Methods
Cell culture
Blood samples derived from patients and their parents
were used to establish lymphoblastoid cell lines as de-
scribed by Nishimoto et al. [9].
Genomic DNA extraction
Isolation of genomic DNA from human blood was carried
out using a standard phenol-chloroform protocol with
minor modifications or the Qiagen automated extraction
procedure, following the manufacturer’s recommendations.
Whole exome sequencing
Whole exome sequencing in trios, followed by Sanger
sequencing of PHF21A variants, was performed on a
clinical basis for four of the seven patients. For the
paired-end pre-capture library procedure, genomic DNA
was fragmented by sonicating and ligating to the Illu-
mina multiplex PE adapters. The adapter-ligated DNA
was then PCR amplified using primers with sequencing
barcodes. For the target enrichment exome capture pro-
cedure, the pre-capture library was enriched by hybridiz-
ing to biotin-labeled VCRome 2.1 in-solution exome
probes [10] at 47 °C for 64–72 h. For massively parallel
sequencing, the post-capture library DNA was subjected
to sequence analysis on Illumina HiSeq platform for 100
bp paired-end reads [11]. The following quality control
metrics of the sequencing data were generally achieved:
> 70% of reads aligned to target, > 95% of the target
bases covered at > 20×, 85% of the target bases covered
at > 40×, mean coverage of target bases > 100×, and SNP
concordance to genotype array > 99%.
Targeted gene panel sequencing
Five hundred and twenty genes associated with ID/cog-
nitive impairment (Additional file 1: Table S1) were ana-
lyzed in trios (propositus, mother, and father) from a
cohort of 947 patients referred for ID. These genes were
selected by their involvement in ID from a literature
search on PubMed. Sequencing with this targeted gene
panel was performed for patients 2, 4, and 6.
SeqCap EZ Capture kit (Roche) and 75 bp paired-end
reads sequencing on a Nextseq550 Illumina sequencer
were performed following the manufacturers’ recom-
mendations. Greater than 95% of target bases were rou-
tinely covered at > 30×. Parentage was confirmed using
several rare inherited variants.
For two GeneDx cases of patients 3 and 7, the SureSe-
lect Human All Exon V4 (50 Mb) and the IDT xGen Ex-
ome Research Panel v1.0 kits were used".
Sanger sequencing
All variants identified by whole exome sequencing were
confirmed by Sanger sequencing of the genomic DNA ex-
tracted from the blood of patients. Primer pairs encom-
passing the individual sequence variants were designed for
Sanger sequencing. PCR reactions were carried out in a
total volume of 50 μl using GoTag® Green Mastermix
(Promega). The conditions for PCR included an initial de-
naturation at 95 °C for 4min, 40 cycles consisting of a
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denaturation at 95 °C for 30 s, annealing at 60 °C for 1
min, and extension at 72 °C for 1min followed by a final
extension for 5min at 95 °C. Approximately 5 μl of the re-
action product was run on a 1% agarose gel containing
ethidium bromide (100mg/ml). The PCR products were
purified by a standard protocol and sequenced using the
Big Dye® Version 3.1 Cycle Sequencing kit (Applied Bio-
systems) after confirming the sizes of the amplicons.
Real-time PCR
Isolation of total RNA from lymphoblastoid cell lines was
performed using the RNeasy Plus Mini kit (Qiagen) follow-
ing the manufacturer’s protocol. Total RNA from the hu-
man brain and fetal brain, as well as other tissues (Human
Total RNA Master Panel II, Cat# 636643, Clontech), were
also used for RT-qPCR. The cDNA synthesis was per-
formed from 1 μg of total RNA using the RevertAid First
cDNA Synthesis Kit (Thermo Scientific) following the man-
ufacturer’s instructions. Real-time PCR was carried out in a
20-μl reaction volume containing 2 μl cDNA, 2.5 μM pri-
mer, and 10 μl FastStart DNA Green Master (Roche).
RT-PCR
RNA was transcribed into cDNA with the QuantiTect
Reverse Transcription Kit (Qiagen). Resulting cDNA was
amplified using PCR primers (available upon request) by
PrimeStar GXL (Takara) following the manufacturer’s
instructions.
MiSeq sequencing
RT-PCR products were pooled. Nextera XT DNA Prep-
aration kit (Illumina) was used to create a DNA library,
which was fragmented and tagged with adaptors accord-
ing to the manufacturer’s protocol. Samples obtained
were pooled and sequenced in MiSeq (Illumina). Result-
ing data were aligned to the human genome reference
sequence (GRCh37/hg19) using BWA (Burrows-Wheeler
Aligner; v0.7.6). The Genome Analysis Toolkit (GATK;
v2.1-10) enabled indel realignment and base quality
score recalibration. Variants with a quality score > 30
and alignment quality score > 20 were annotated with
SeattleSeq SNP Annotation.
Protein-DNA modeling
We modeled the AT Hook region using the one-to-one
threading expert mode platform of Phyre2 [12]. The AT
Hook-DNA complex structure was used as a template
(PDBID: 2EZE). The chain A within 2EZE having the
peptide (25 amino acids long) of the AT Hook region
was aligned and used for final modeling. Protein-DNA
modeled structures were analyzed, and figures were gen-
erated using PyMOL (W.L. DeLano, The PyMOL Mo-
lecular Graphics System, 2014, version 1.8, Schrödinger
LLC: http://www.pymol.org.10.1038/hr.2014.17.)
Clinical reports
Patient 1 (c.1955delC, p.Pro652LeufsX104)
Patient 1 is a 13-year-and-6-month-old Caucasian fe-
male with a history of ID, ASD, focal epilepsy, motor
apraxia, attention deficit hyperactivity disorder (ADHD),
and dysmorphic features. She was born full term by
spontaneous vaginal delivery and weighed 4 kg (99th
centile). Around 4months of age, she was noted to have
hypotonia, specifically poor head and neck control. She
sat independently at around 8months, walked at 21–22
months, and spoke her first words at 18 months, but was
not speaking full sentences until 5 years of age. She cur-
rently speaks both English and Romanian fluently. She
repeatedly displayed absent reflexes on examination
prompting an electromyogram, nerve conduction stud-
ies, and an MRI of the brain and spine. The MRI of the
spine revealed a low-lying conus but no tethered cord.
The remaining studies were normal.
Neurobehavioral concerns began at 10months of age
when she displayed repetitive movements and wringing of
her hands. At 3 years and 11months, she was diagnosed
with pervasive developmental disorder-not otherwise speci-
fied (PDD-NOS) (Table 1). Around 5 years of age, she ex-
hibited muscle twitching. She had two events at 9 years of
age in which she was described to have had altered aware-
ness or was unresponsive. During the same year, she fell
limp and had eye deviation, weakness, altered mental status,
smacking of lips, and vomiting. A physical exam revealed
facial droop, unbalanced waddling gait, and perseveration.
An electroencephalogram (EEG) showed intermittent focal
slowing in the right temporal area. She was diagnosed with
complex partial seizures, which have been well controlled
with oxcarbazepine. She was also diagnosed with ADHD.
Her most recent neuropsychological testing revealed that
her Wechsler Intelligence Scale for Children-Fifth Edition
(WISC-V) full-scale score was very low (first centile). She
scored poorly across visual spatial fluid reasoning, working
memory, and processing speed indexes but performed in
the high average range on the verbal comprehension index
(77th centile). She continues to struggle with independent
planning and organization and becomes frustrated with
challenging tasks. She has few close friends and exhibits im-
mature social skills. She has a significant anxiety disorder
and continues to progress, but her deficits in attention and
executive function continue.
At 11 years of age, she weighed 54.9 kg (95th centile)
with a height of 159.6 cm (> 97th centile) and head cir-
cumference of 58 cm (> 97th centile). Her mother has a
head circumference of 59 cm (> 97th percentile), and by
observation, her father had a large-sized head. She had
abundant scalp hair and a very pronounced widow’s peak
with a receding anterior hairline laterally. Dysmorphic fea-
tures included significant bilateral epicanthal folds, a
broad nasal bridge, a broad nasal tip (Fig. 1a), one café-au-
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Fig. 1 (See legend on next page.)
Kim et al. Molecular Autism           (2019) 10:35 Page 5 of 15
lait spot (Fig. 1b), several moles on her head below the
hairline, and low-set and posteriorly rotated ears, which
appeared very fleshy (Fig. 1b–d). She had a Darwinian tu-
bercle (Fig. 1) on the left ear and an ear length of 6 cm
(50th centile). Her columella was wide, short, and hypo-
plastic (Fig. 1a–c). She has mild tapering fingers and clino-
dactyly (Fig. 1f). Her hand measurements were 16 cm and
15 cm (60th centile), while her feet were at the 75th cen-
tile and appeared completely flat. She displayed brachy-
dactyly of the toes (Fig. 1g). She had a hoarse voice, kept
her mouth open, and sucked her thumb. Her nipple was
inverted on the left, and she had a supernumerary nipple
on the same side (Fig. 1h). She was obese with a BMI of
22 (94th centile) (Fig. 1e).
Other tests completed for this patient include an extensive
metabolic workup, chromosome analysis, 15q subtelomeres,
oligoarray/SNP analysis, methylation studies for Prader-Willi
and Angelman syndromes, and an evaluation of the follow-
ing genes: MELAS, MERRF, NARP, MECP2, PTEN, TSC1,
and TSC2.
Patient 2 (c.1285G>A, p. Gly429Ser)
Patient 2 is a 3-year-and-4-month-old Caucasian male born
to non-consanguineous parents. He has an older brother
without any medical issues and no significant family his-
tory. He was born at full term after an uneventful preg-
nancy. At birth, his weight was 3.86 kg (84th centile), his
length was 54 cm (99th centile), and his head circumference
was 35 cm (66th centile). His initial development was nor-
mal. At 11months of age, he had his first seizure episode
with flexor spasms. An electroencephalogram showed hyp-
sarrhythmia. Both the clinical presentation and EEG im-
proved under treatment with vigabatrin. At 20months, he
was placed on combination therapy (with vigabatrin and
valproate) due to worsening epilepsy. He was referred to
genetics at 24months of age. At that time, it was noted that
the number of spasms had decreased from one episode per
day at 11months of age to two episodes per month, with
each episode being a few seconds in duration. The treat-
ment at that time was vigabatrin 90mg/kg/day.
At 24 months, he weighed 15.5 kg (> 97th centile), with
a height of 95 cm (99th centile) and a head circumfer-
ence of 50 cm (90th centile). Psychomotor milestones
were delayed, sitting at 10 months, walking at 34 months,
and language limited to monosyllables and reduplication
of the same syllable. He displayed symptoms of behavior
disturbance, including motor agitation and frequent
screams. At 40 months, there was no sign of ASD re-
ported. There were no sleeping or eating difficulties, no
history of regression, and no stereotypic movement. He
had a round face with a high forehead, a broad nasal
bridge, mild bitemporal narrowing, synophrys (without
other excess of body hair), macrostomia with conical
teeth, normal ears, and a normal palate (Fig. 1i–l). He
had clinodactyly on both hands (Fig. 1m–n) and syndac-
tyly of the second and third toes on both feet. He also
had myopia. Radiographic evaluation—including an ab-
dominal ultrasound; x-rays of the rachis, pelvis, and
limbs; and a brain MRI—was normal. A first-tier meta-
bolic screening was normal (amino acid chromatography
in blood and urinary oligosaccharides and mucopolysac-
charides). As no specific disease could be suspected on
the basis of the clinical presentation, no targeted genetic
screening was performed, and whole exome sequencing
was proposed to the parents. This patient was identified
through GeneMatcher [13].
Patient 3 (c.1956delT, p.Pro652ProfsX104)
Patient 3 was initially evaluated in a neurogenetics clinic
at 9 years and 9months of age for seizures, ID, and a be-
havior disorder. She was born full term after an uncom-
plicated pregnancy and delivery to a G4P4 mother. Her
birth weight was 3.4 kg (64th centile), and no perinatal
complications were noted. She was developmentally de-
layed, sitting at 7 or 8 months; combat crawling at 12
months, which evolved to a four-pronged crawl; and
walking at 19 months. With regard to language develop-
ment, she babbled between 8 and 10 months and devel-
oped single words by 12 to 18months of age.
Behavioral concerns began fairly early. At the age of
two, she was biting other children and having crying fits.
She was started on fluoxetine at about 4 years of age
with some improvement in behavior. At the age of five,
the behavior concerns persisted, and she began to have
episodes related to seizures, consisting of repeated eye
blinking and eye rolling that lasted for up to hours at a
time. During this time, she also had poor sleep. She was
therefore referred to a neurologist. An EEG, done
(See figure on previous page.)
Fig. 1 Facial, limb, and full body pictures of patients with PHF21A mutations. a Facial picture of patient 1 showing a broad nasal bridge, broad
nasal tip, and significant bilateral epicanthal folds. b Profile view showing a café-au-lait spot on the right cheek, and her columella was wide,
short, and hypoplastic. c Profile showing a Darwinian tubercle on the low-set left ear. d Fleshy and posteriorly rotated ears. e Full body image
showing truncal obesity. f Hands showing mild tapering fingers and clinodactyly. g Feet were completely flat and showed brachydactyly of the
toes. h Inverted nipple on the left and left-sided polythelia. I–L Patient 2 with a round face, a high forehead, a broad nasal bridge, mild
bitemporal narrowing, synophrys, and macrostomia with conical teeth. m, n Tapering fingers and clinodactyly in patient 2. O, P Face showing a
thinner upper lip and a prominent chin in patient 3. q Patient 3 showing tapering fingers and clinodactyly. r, s Patient 4 with mild plagiocephaly
and hypertelorism. t normal fingers of patient 4. u Minor syndactyly of toes two and three in Patient 4. v–aa Patient 6 showing midface
hypoplasia, a thin upper lip, and a prominent chin in v and z, aa
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through an epilepsy monitoring unit, revealed seizure ac-
tivity precipitated by eye closure that occurred diffusely
over the occipital region. She was started on levetirace-
tam at that time and was concurrently treated with flu-
oxetine, guanfacine, and lisdexamfetamine for behavioral
issues. At the age of 9 years and 9months, she was hav-
ing the eye blinking episodes for longer than 10min ap-
proximately two to three times a week for which
lorazepam was given.
Her past medical history is relatively non-contributory
for major illness or complications. Due to concern for loss
of cognitive skills at the age of 9 years, a brain MRI was
performed which was normal. A neurological examination
of the patient was normal without focal deficits, both cen-
trally and peripherally. She exhibited a mostly slow and
wobbly gait, being unsteady at times. Her speech was ro-
botic with quick short responses. She had a thinner upper
lip, a prominent chin (Fig. 1o, p), clinodactyly, and taper-
ing fingers on both hands (Fig. 1q). At the age of 12 years
and 5months, it became apparent that the peak in behav-
ioral episodes and the seizure activity occurred at a time
just prior to the onset of her menstrual cycle. She contin-
ued to have interrupted sleep during the night. Normal
testing included chromosomal microarray, fragile X,
plasma amino acid analysis, urine organic acid levels, and
pyruvate levels. Family history was non-contributory. Due
to the continued clinical concerns, whole exome sequen-
cing was pursued for the patient.
Patient 4 (c.1738C>T, p.Arg580Ter)
Patient 4 is a 10-year-old male with no family history of
neurodevelopmental disorders. The patient experienced
psychomotor retardation with sitting at 12 months and
walking at 27 months. He was also noted to have lan-
guage and fine motor delays. At the age of 6 years, he
was diagnosed with mild ID including difficulties with
reasoning and abstraction, attention deficit disorder, and
verbal and visual-constructive dyspraxia. He also had hip
dysplasia, valgus feet, mild plagiocephaly, hypertelorism
(Fig. 1r–s), and minor 2–3 toe syndactyly (Fig. 1u). The
patient had multiple generalized tonic-clonic seizures at
9 years of age. Interictal EEG was normal, but a seizure
was recorded in the left temporal region, for which he
was treated with valproate. At the age of 10, the patient
experienced cognitive regression following an episode of
partial seizures, gaze fixation, and gestural automatism.
An EEG recording showed diphasic spikes in the two
posterior regions, which diffused into the anterior re-
gions and produced continuous waves of 20 to 40 s dur-
ing sleep. Levetiracetam therapy did not control the
seizures, and thus, clobazam was prescribed with partial
alleviation.
A brain MRI at age nine was normal. Fragile X testing,
a chromosome analysis performed on lymphocytes, and
chromosomal microarray were normal. Targeted se-
quential studies of the ARX, FOXP2, and GRIN2A genes
did not find any abnormalities. A panel of 450 ID genes
was sequenced, with negative results. Whole exome se-
quencing in the patient and both of his parents was
performed.
Patient 5 (c.1471dupT, p.Cys491LeufsX81)
Patient 5 is an 18-year-old Hispanic male. He was born
at 39 weeks gestation to a 15-year-old G1P1 mother via
Cesarean section. The father was 16 years old at the time
of birth. Consanguinity was denied. The pregnancy was
complicated by possible early exposure to alcohol and
marijuana. Birth weight was 3856 g (84th centile), and
birth length was 48.3 cm (20th centile). After birth, he
was noted to have difficulty breathing, sucking, and
swallowing. He required supplemental oxygen and spent
1 week in the neonatal intensive care unit due to hyp-
oxia, feeding difficulties, and jaundice. Over time, he was
diagnosed with developmental delay, ID, attention deficit
disorder, bipolar disorder, and ASD. He sat without as-
sistance at 5 to 6 months of age, crawled at 7 to 8
months of age, and walked at 18 months of age. He
spoke his first words at 1 year of age and began to com-
bine words at 3 years of age. A speech assessment at 4
years of age revealed delayed receptive and expressive
language skills—characteristic of a 2 to 3 year old—and
poor speech intelligibility. Throughout his education, he
was enrolled in special education classes. He had a his-
tory of recurrent ear infections requiring placement of
multiple sets of pressure equalization tubes. An audiom-
etry evaluation performed at 5 years of age revealed
slight conductive hearing loss on the right and normal
hearing on the left. An MRI of the brain performed at 5
years of age was normal. He was later diagnosed with
obesity and obstructive sleep apnea.
At 17 years and 10 months of age, his height was 171
cm (26th centile), his weight was 115 kg (99.5th centile),
and his body mass index was 39.3 (99.6th centile). He
was non-dysmorphic, but was noted to have large ear-
lobes and bilateral fifth finger clinodactyly (Table 1). A
previous workup included chromosome analysis, a
microarray-based copy number variant analysis, plasma
amino acids, urine organic acids, ammonia, NSD1 se-
quencing, and fragile X testing, all of which were nor-
mal. Whole exome sequencing was performed on a
clinical basis.
Patient 6 (c.1738C>T, p.Arg580Ter)
This child is the third boy of four, born to non-
consanguineous parents of French and Tunisian ances-
try. He was born at 38 weeks gestation by Cesarean sec-
tion because of macrosomia. His birth parameters were
4610 g for weight, 52 cm for length, and 38 cm for head
Kim et al. Molecular Autism           (2019) 10:35 Page 7 of 15
circumference. At birth, he had no hypotonia or feeding
difficulties. He sat at 17 months, walked independently
at 26 months, and spoke his first words at 2 years and
first phrases at 5 years. Neuropsychological evaluation at
4 years and 5months (WPPSI IV) showed global devel-
opmental delay, with skill levels equivalent to a 2-year
and 6-month to a 3-year and 4-month level. He needed
aid at school and entered a special school for intellec-
tually disabled children at 5 years and 9months. He had
recurrent episodes of otitis media and a tendency to be
constipated, but no seizures, regression, sleeping difficul-
ties, or behavior disorders were reported. A brain MRI
was normal, as well as a renal ultrasound. Standard bio-
chemical and metabolic tests were normal as were fragile
X testing and SNP array.
At last examination, at 5 years and 3months, the pa-
tient had a weight of 23.7 kg (+ 2.5 SD), a height of 113
cm (+ 1 SD), and a head circumference of 54.2 cm (+ 2
SD). He had midface hypoplasia, thin upper lip, and
prominent chin (Fig. 1v, z). He had no noticeable dis-
tinctive features of his hands and feet, and no skin le-
sions. Both testes were palpable. His neurologic
examinations were normal. A targeted panel of 520
genes associated with ID/cognitive impairment was
performed.
Patient 7 (c.2024delA, p.Gln675ArgfsX81)
At the time of assessment, patient 7 was an 18-year-old
Asian female, the first-born child of non-consanguineous
Hmong parents, who subsequently had four additional
healthy, developmentally normal children. She was born at
full term after an uneventful pregnancy. At birth, her
weight was 3.062 kg (35th centile), her length was 48.3 cm
(32nd centile), and her head circumference was not avail-
able. Her early motor development was normal. She had
delayed speech with first words at 18months, followed by
additional developmental delays and eventual development
of cognitive impairment. At 3 years, she was diagnosed with
PDD-NOS, due to loss of social and behavioral skills start-
ing around 2 years of age, sensitivity to loud sounds, im-
paired coordination, and difficulties with balance.
She had a history of behavioral aggression throughout
her schooling, particularly with regard to ownership and
sharing, which intensified between 16 and 17 years of
age, associated with diagnoses of obsessive-compulsive
disorder and anxiety. She had one acute out-of-character
behavioral episode, characterized by disinhibited behav-
ior and unusual delusions, without hallucinations, lasting
a few days at age 17, for which brain MRI, 24-h continu-
ous EEG, and subsequent neurological evaluation were
negative. She has never had any observed seizures.
In an assessment at 18 years, she was noted to need
substantial help with self-care activities and could not
understand or follow instructions. Her interactions and
behaviors were immature, characterized as a 4-year-old
level by her school evaluations. She had short stature
and obesity (weight 88.2 kg, > 98th centile; height 153.0
cm, 6th centile; BMI 37.7 kg/m2, 98th centile) with
macrocephaly (head circumference 58 cm; > 98th centile)
(Table 1). She had a history of continuously gorging or
binge eating to the point of vomiting, requiring her par-
ents to restrict her food intake.
She was mildly dysmorphic, with sparse lateral eye-
brows, telecanthus, left preauricular pit, prominent cupid
bow configuration of the upper lip, and slack facial expres-
sion. She had numerous self-inflicted, skin-picking lesions
on her arms, in various stages of healing, and one hyper-
plastic keloidal scar elsewhere. Her speech was fluent but
very simple, with sound substitution errors very typical of
a young child. There was periodic echolalia, in addition to
outbursts of out-of-context speech, without regard to
interrupting other speakers. Negative genetic testing
included Prader-Willi/Angelman syndrome methyla-
tion and MLPA, fragile X, and CNV analysis via SNP
microarray. However, areas of homozygosity were
identified across multiple chromosomes, with an over-
all percentage of autosomal/genomic homozygosity of
2.5%. No candidate recessive genes were identified
within the homozygous regions. As no specific disease
could be suspected on the basis of the clinical presen-
tation, family trio sequencing of GeneDx’s Autism/ID
Xpanded Panel with 2308 genes was performed, using
oral rinse samples from her and both parents. This
patient was identified through GeneMatcher [13].
Results
Using whole exome sequencing or ID gene panel se-
quencing, we identified six unique variants in seven pa-
tients. Four were frameshift variants, three of which are
de novo and potentially produced aberrant elongated
proteins (in patients 1, 3, and 7), while the fourth (in pa-
tient 5) could produce a shortened protein that also has
the addition of 80 aberrant amino acids. Two patients (4
and 6) have identical de novo nonsense variants, and the
last was a de novo missense variant (patient 2) (Table 1,
Figs. 2 and 3). Sanger sequencing confirmed the pres-
ence of all variants in the probands and the absence of
the variants from the available parents.
In patients 1 and 3, we identified a de novo c.1955delC
variant (NM_001101802.1) causing a frameshift
(p.Pro652LeufsX104) and a de novo c.1956delT variant
causing a frameshift (p.Pro652ProfsX104), respectively,
both in exon 18 and predicted to produce 754-amino-
acid (aa) elongated proteins compared to the wildtype
PHF21A of 680 aa (NP_001095272.1) (Fig. 3 (A, C)). As
a result of the frameshift in patient 1, this chimeric pro-
tein is 74 aa longer, comprised of the N-terminal 651 aa
of wildtype PHF21A followed by an aberrant 103 aa (aa
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652–754). In patient 3, the mutant protein has an aber-
rant 102 aa sequence (aa 653–754), same as patient 1,
except for a difference at the 652nd residue.
In patient 2, we found a de novo missense variant
c.1285G>A at the last nucleotide of exon 13 leading to
an aa substitution p.Gly429Ser (Fig. 2), at a highly con-
served residue within the AT Hook domain, which binds
AT-rich DNA (Fig. 3 (B)). It is predicted to be deleteri-
ous using MutationTaster and SIFT but not by Poly-
phen2. Because the variant is predicted to alter donor
splice scores (SFF score 75.43 versus 87.56; MaxEntScan
3, 71 versus 8, 41 and NNSplice score 0, 43 versus 0,
99), cDNA libraries obtained by RT-PCR from the blood
of patient 2 were pooled and sequenced using Illumina
MiSeq. It did not reveal any aberrant splice transcripts,
indicating this variant did not disrupt the splicing mech-
anism. In order to understand the structural basis of this
mutation (Gly429Ser), we modeled native as well as mu-
tated AT Hook region based on a previously solved
structure (PDBID: 2EZD) of AT Hook region complexed
with DNA [14] (Fig. 4a). The presence of a hydroxyl
group (polar) in the side chain of serine relative to gly-
cine (no side chain) creates a repulsive charge due to its
proximity to the negatively charged phosphate backbone
of DNA (Fig. 4b).
Glycine 429, in the central typical glycine-arginine-
proline tripeptide GRP motif [15] of the AT Hook do-
main, is evolutionarily fully conserved in all nine avail-
able PHF21A orthologs (Fig. 5). Given that the other six
mutations are nonsense or frameshift mutations leading
to loss-of-function, this missense mutation likely results
in a non-functional PHF21A mutant. The non-
functionality likely arises from the compromise in AT
Hook: DNA interactions. The phosphate group (phos-
phoric acid, PO4
2−) of DNA makes it a weak acid with a
negative charge. Much of the AT Hook’s DNA domain/
motif is dominated by basic aa residues like lysine and
arginine, including its four core Arg-Gly-Arg-Pro
(RGRP) residues, which are dominated by a positive
charge. Replacement of glycine with serine may likely
interfere with the binding of DNA, resulting in a dimin-
ished binding affinity, due to the polar mutant serine
with a partial negative charge, which would create
charge repulsion. This indicates that the AT Hook do-
main may be critical for the function of PHF21A.
The same de novo nonsense change c.1738C>T in exon
17 was identified in patients 4 and 6 (Table 1, Fig. 2) and cre-
ates a premature stop codon (p.Arg580Ter, Fig. 3 (D, F)).
The premature stop codon is located 48 nucleotides up-
stream from the exon 17–18 junction in patients 4 and 6,
without satisfying the “> 50–55 nucleotide rule” of more than
50 nucleotides upstream from the last exon-exon junction
for nonsense-mediated mRNA decay [16, 17]. Therefore, it is
predicted to not elicit nonsense-mediated mRNA decay, and
a truncated protein without the LZD2 domain and C-
terminal domain would likely be expressed (Fig. 3 (D, F)).
A heterozygous c.1471dupT variant in exon 15 was
identified in patient 5 (Fig. 2), which causes a frameshift
Fig. 2 Mutations in PHF21A and domain structure of the protein. Six mutations located in corresponding exons are depicted. Eighteen exons are
represented by light blue boxes with corresponding numbers below connected by a horizontal black line representing the introns. The arrow in
the intron shows the transcription direction. The UTRs are depicted by gray boxes, and the diagonal lines indicate not to scale. Note that the size
of exons, mutation location, and protein domains are to scale; however, the size of the introns and UTRs are not. The identified deletions,
duplication, and point mutations on the cDNA level (NM_001101802.1) are depicted in red above the exons. The nonsense mutation c.1738C>T
has been found in two patients. The dotted black lines connect the corresponding exons encompassed within each functional domain
demarcated by a corresponding amino acid residue number (NP_001095272.1)
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Fig. 3 PHF21A functional domains in wildtype and theoretical missense and truncated or altered proteins in seven subjects. PHF21A contains two leucine
zipper domains (LZD1 and LZD2), one AT Hook domain, one PHD zinc finger domain, and one intrinsically disordered region (IDR). The amino acid positions of
all domains are indicated as numbers below the domain structures. Aberrant amino acid sequences produced by frameshifts are indicated as brown bars,
under which the starting aberrant residue is indicated as a number. Note that the size of the functional domains is to scale; however, the regions connecting
them are not. In patient 1, the preserved 651 amino acids are followed by 103 aberrant amino acids, which results in an aberrant elongated protein of 754 aa.
In patient 2, the missense mutation indicated as a red dot is located in the AT Hook domain. In patient 3, the first 652 amino acids in the wildtype protein
were followed by 102 aberrant amino acids, resulting in a 754 aa elongated mutant protein. A 754 aa elongated chimeric protein in patient 7 is composed of
the 674 aa wildtype protein plus 80 aberrant amino acids. If expressed, the truncated protein in patients 4 and 6 loses a LZD2 domain, and in patient 5, the
LZD2 domain as well as the PHD finger domain, both essential for binding H3K4me0, is missing. In patients 1, 3, and 7, the IDR has been truncated as shown
by the partial blue box
Fig. 4 a Structure of AT Hook: DNA complex (left panel) represented in ribbon diagram (PDBID: 2EZD). AT Hook motif in pink interacts with the minor groove
of DNA in salmon. AT Hook motif in lemon of PHF21A was modeled (middle panel) based on the PDBID: 2EZD. The mutated AT Hook (Gly429Ser) motif in
marine was similarly modeled (right panel) based on the PDBID: 2EZD. b Superposition of the modeled structure of AT Hook region in native form (Gly) and in
mutated form (Ser). The presence of serine in the mutated form creates a charge repulsive environment, which is not conducive to protein-DNA interaction
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(p.Cys491LeufsX81), and if translated would create a
truncated mutant protein of 570 aa, which is 110 aa
shorter than the 680 aa wildtype PHF21A, composed of
the N-terminal 490 aa of PHF21A followed by 80 add-
itional aberrant aa (Fig. 3 (E)). The premature termin-
ation codon is located 74 bp upstream from the junction
of exons 17 and 18, thus likely to trigger nonsense-
mediated mRNA decay, preventing the expression of the
truncated protein without the PHD finger domain, es-
sential for binding H3K4me0 (Fig. 3 (E)). The
c.1471dupT variant was not seen in his healthy mother,
but the paternal DNA could not be obtained.
In patient 7, a de novo heterozygous variant (c.2024delA)
in exon 18 was identified (Table 1, Fig. 2). It would cause a
frameshift p.Gln675ArgfsX81, which would produce an elon-
gated 754 aa mutant protein with the N-terminal 674 aa of
PHF21A followed by 80 additional aberrant aa (Fig. 3 (G)).
Although the size and composition of the aberrant
PHF21A proteins in patients 1 and 3 are almost identi-
cal, varying only by 1 aa at the 652th residue (leucine in
patient 1 and proline in patient 3), the respective pheno-
types differ. The one nucleotide deletions c.1955delC,
c.1956delT, and c.2024delA in patients 1, 3, and 7, re-
spectively, occur far downstream in the last exon (exon
18) (Fig. 2), creating an identical delayed termination
codon TAG at the same position in exon 18. This is
downstream of the last splice junction (between exons
17 and 18) and therefore does not satisfy the “> 50–55
nucleotide rule” of more than 50 nucleotides upstream
from the last exon-exon junction [16, 17]. This finding
suggests that the mRNAs in patients 1, 3, and 7 are not
likely to be targets for nonsense-mediated mRNA decay.
Consequently, the three elongated aberrant proteins
would likely be expressed (Fig. 3 (A, C, G)).
We have analyzed the wildtype PHF21A protein se-
quence for domains in the C-terminal region using
SMART (https://smart.embl.de/). Apart from the usual
AT Hook region and PHD domain, a low-complexity re-
gion at the C-terminal (aa 650–671) tail is apparent. The
low-complexity region suggests a disordered but import-
ant region for protein function. To obtain a more in-
depth understanding, we analyzed the sequence using
MobiDB, a database of protein disorder and mobility an-
notations (http://mobidb.bio.unipd.it/search). The analysis
clearly indicated an intrinsically disordered region (IDR)
which lies in C-terminal comprising residues 639–680.
Expression pattern of PHF21A in the brain and other
tissues
We investigated the transcript levels of PHF21A by RT-
qPCR in whole human brain and other tissues and found
that PHF21A transcripts were expressed at higher levels
in the whole brain compared to other tissues, including
the heart, kidney, and lung (Fig. 6a). The transcripts
were at least fivefold higher in the brain and twofold
higher in the skeletal muscle relative to lymphocytes,
supporting the possibility that its mutations can cause
the neurological phenotype, impaired motor skills, and
hypotonia seen in our patients.
A comprehensive PHF21A transcript analysis in differ-
ent regions of the brain revealed a ~ 34-fold higher ex-
pression in the fetal brain relative to lymphocytes.
Compared to lymphocytes, levels of PHF21A transcripts
were tenfold higher in the cerebellum, ninefold higher in
Fig. 5 ClustalW multiple alignment of partial protein sequences of PHF21A orthologs. The position of the residue affected by the missense
mutation of PHF21A in patient 2 is marked by an arrow and a red letter in the corresponding segments of the multiple alignment. The amino
acid residues that differ from the sequence of the human PHF21A protein are indicated in violet, and the sequence of the AT Hook domain (aa
425–437 in NP_001095272.1, UniProtKB-Q96BD5) is indicated in green. The mutated amino acid glycine is evolutionarily fully conserved in all nine
available PHF21A orthologs
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the occipital lobe, and fivefold higher in the hippocam-
pus, known to be associated with learning and memory
[18]. The spinal cord and dorsal root ganglion expressed
lower levels of PHF21A transcripts (Fig. 6b). In contrast,
very low levels of PHF21A expression were detected in
the kidney, liver, and lung (Fig. 6a).
Discussion
Three genes within the 2.1Mb genomic critical region at
11p11.2 are the major determinants of PSS, characterized
by multiple exostoses, biparietal foramina, ID, and cranio-
facial anomalies. In 1996, EXT2 was implicated as the
cause of multiple exostoses when a 4-bp EXT2 deletion
causing a frameshift was identified in all affected members
of a family with multiple exostoses [1]. In 2000, ALX4 was
implicated as the cause of biparietal foramina in PSS with
the identification of ALX4 point mutations: a one-
nucleotide deletion and a missense variant in two unre-
lated families affected with biparietal foramina [3].
Although we reported that PHF21A was associated with
ID and craniofacial anomalies by the positional cloning of
two patients with balanced translocations in 2012 [4], no
point mutations affecting this gene had been reported to
confirm its deleterious impact until three patients with de
novo truncating mutations were reported very recently [8],
while this manuscript was being prepared. Taking into ac-
count that one out of the three reported patients has ASD
[8], we also identified an additional three patients with ASD
(patients 1, 5, and 7), further suggesting that PHF21A is a
novel ASD gene. Patients 1 and 3 have very similar muta-
tions, differing by only one amino acid, yet only patient 1
has ASD. Intriguingly, obesity may be another feature
caused by PHF21A mutation, seen in three of our patients
(patients 1, 3, and 5; Fig. 1e, Table 1), as well as in a female
with a balanced translocation and PHF21A truncation [4]
(Table 1).
The common phenotypes seen in all seven patients re-
ported here are developmental delay, ID, language delay,
Fig. 6 Transcript levels of PHF21A in the brain and other human tissue as determined by RT-qPCR. a A higher PHF21A expression was detected in
the adult brain compared to the heart, kidney, liver, lung, skeletal muscle, and lymphocytes. b PHF21A is abundantly expressed in the fetal brain.
High levels of PHF21A transcripts were also detected in the cerebellum, occipital lobe, postcentral gyrus, insula, cortex, and hippocampus
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and impaired motor skills. Seizures were observed in
four patients. The existence of novel genes at 11p11.2
for hypotonia [6] and neurobehavioral problems [7] were
suggested previously. The hypotonia in three patients
and neurobehavioral problems in six patients here sug-
gest that PHF21A is a contributory gene for these clin-
ical features in PSS.
The extra C-terminal aberrant tail in the elongated
proteins from patients 1, 3, and 7 could act dominant
negatively by a gain-of-function mechanism, which
might result in a discrepant phenotype from that caused
by haploinsufficiency. However, significant phenotype
differences were not seen in these patients when com-
pared to the rest of the cohort (Table 1).
We also found a new intrinsically disordered region
(IDR) domain at the C-terminus of PHF21A (aa 639–680
in NP_001095271.1). If proteins are produced from the
nonsense or frameshift variants in any of our patients, this
region would be deleted or truncated (Fig. 3) and thus
might have an important function, although additional pa-
tients and functional characterization would be needed for
further confirmation. IDR domains provide flexibility to
the protein and facilitate different conformational require-
ments for binding modifying enzymes as well as their re-
ceptors [19]. These IDRs are particularly prominent
within proteins involved in cell signaling, transcription,
and chromatin remodeling functions [20, 21]. At a first
glance, missense variants in IDR (639–680 aa) at the C-
terminus of PHF21A do not seem constrained in gnomAD
(Genome Aggregation Database, https://gnomad.broadin-
stitute.org/). However, among the 32 heterozygous mis-
sense variants in the IDR listed in gnomAD, only 4 rare
variants (p.Glu678Ala, p.Ser668Arg, p.Ser663Tyr, and
p.Thr650Asn), each found in 1 or 2 individuals among
over 100,000 people, are predicted as probably or possibly
damaging. These findings raise the possibility that among
the background of neutral missense variants, some rare
missense variants in this region could be pathogenic. Al-
ternatively, the IDR of PHF21A might be intolerant to
truncation, but tolerant to missense variants.
The profound expression in the human fetal brain em-
phasizes the role of PHF21A in early human develop-
ment, which is consistent with features in our patients,
such as developmental delay, ASD, ADHD, and epilepsy
observed at an early age (Table 1).
PHF21A encodes a protein that specifically binds
unmethylated H3K4 as part of a histone demethylase
complex that participates in suppression of neuronal gene
expression. Histone-modifying enzymes such as histone
methyltransferases [22, 23] and demethylases [24–26]
have previously been found mutated in syndromic ID.
PHF21A is neither a writer nor an eraser, but instead spe-
cifically binds unmethylated histone H3K4me0 as a reader
in a KDM1A multiprotein complex [27]. This suggests for
the first time that a non-catalytic protein targeted to an
unmethylated histone site is critical for normal cognitive
function and craniofacial development.
Among the other components of the KDM1A demethy-
lase complex, one balanced translocation disrupting ZMYM3
[28] and one familial missense mutation of ZMYM3 [29]
have been reported. Most importantly, three boys with three
different de novo heterozygous missense mutations in
KDM1A have been reported, sharing craniofacial anomalies,
developmental delay, and hypotonia [30]. Furthermore, one
patient with KGB syndrome and Kabuki syndrome has been
reported to have a de novo missense mutation of KDM1A,
along with a de novo 3-bp deletion of another gene,
ANKRD11 [31]. Collectively, mutations of four components
in the KDM1A demethylase complex have been identified in
syndromic ID patients. The parallels between KDM1A,
PHF21A, ZMYM2 [32], and ZMYM3 suggest that other gen-
etic loci underlying ID may encode other proteins that par-
ticipate in protein complexes involving KDM1A or
potentially other demethylases.
Limitations
More functional studies on the AT Hook domain and
IDR of PHF21A are required regarding its function in
the neurodevelopmental process as a reader of unmethy-
lated histone H3K4me0. Missense or truncating muta-
tions in IDR in human patients need to be found to
reinforce its functional role. Since blood from the pa-
tients was not available while this manuscript was being
prepared, we could not demonstrate that the truncated
variants without the IDR are expressed, precluding any
definite conclusions about the role of this region.
Conclusion
In this study, we have identified seven heterozygous cod-
ing mutations, among which six are known to be de
novo. Four frameshift mutations and one nonsense mu-
tation in two patients are loss-of-function variants. Based
on the patient’s phenotype, one heterozygous missense
mutation in the AT Hook domain is as deleterious as
other mutations and, based on functional predictions,
likely to cause loss of PHF21A function. These muta-
tions support the hypothesis that haploinsufficiency is
the underlying pathogenic mechanism of PHF21A. The
overlapping phenotypes in our patients are developmen-
tal delay, ID, language delay, and impaired motor skills.
Additionally, some of our patients display ASD, epilepsy,
ADHD, anxiety disorder, hypotonia, tapering fingers,
clinodactyly, and syndactyly, which extends the clinical
features caused by PHF21A mutations. Furthermore, we
discovered that PHF21A is abundantly expressed in the
human fetal brain and skeletal muscle, which is consist-
ent with the neurological phenotypes and hypotonia.
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